These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9523308)

  • 1. Risedronate gastrointestinal absorption is independent of site and rate of administration.
    Mitchell DY; Eusebio RA; Dunlap LE; Pallone KA; Nesbitt JD; Russell DA; Clay ME; Bekker PJ
    Pharm Res; 1998 Feb; 15(2):228-32. PubMed ID: 9523308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dosing regimen on the pharmacokinetics of risedronate.
    Mitchell DY; Heise MA; Pallone KA; Clay ME; Nesbitt JD; Russell DA; Melson CW
    Br J Clin Pharmacol; 1999 Oct; 48(4):536-42. PubMed ID: 10583024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.
    Mitchell DY; Barr WH; Eusebio RA; Stevens KA; Duke FP; Russell DA; Nesbitt JD; Powell JH; Thompson GA
    Pharm Res; 2001 Feb; 18(2):166-70. PubMed ID: 11405286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
    Ogura Y; Gonsho A; Cyong JC; Orimo H
    J Bone Miner Metab; 2004; 22(2):120-6. PubMed ID: 14999522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
    Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
    Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
    Ogura Y; Gonsho A; Cyong JC; Orimo H
    J Bone Miner Metab; 2004; 22(2):111-9. PubMed ID: 14999521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers.
    Mitchell DY; Eusebio RA; Sacco-Gibson NA; Pallone KA; Kelly SC; Nesbitt JD; Brezovic CP; Thompson GA; Powell JH
    J Clin Pharmacol; 2000 Mar; 40(3):258-65. PubMed ID: 10709154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
    Miller PD; Brown JP; Siris ES; Hoseyni MS; Axelrod DW; Bekker PJ
    Am J Med; 1999 May; 106(5):513-20. PubMed ID: 10335722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate for Paget's disease of bone.
    Med Lett Drugs Ther; 1998 Aug; 40(1034):87-8. PubMed ID: 9731243
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S; Pavelka K; Cline GA; Hosterman MA; Barton IP; Cohen SB; Bensen WG
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
    Lanza FL; Hunt RH; Thomson AB; Provenza JM; Blank MA
    Gastroenterology; 2000 Sep; 119(3):631-8. PubMed ID: 10982755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Episcleritis secondary to risedronate].
    Viñas G; Olivé A; Holgado S; Costa J
    Med Clin (Barc); 2002 Apr; 118(15):598-9. PubMed ID: 12015954
    [No Abstract]   [Full Text] [Related]  

  • 16. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
    Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
    Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
    Park JW; Byun Y
    Arch Pharm Res; 2014 Dec; 37(12):1560-9. PubMed ID: 24254935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
    Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.